{"id":604181,"date":"2022-06-15T20:38:01","date_gmt":"2022-06-15T20:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604181"},"modified":"2022-06-15T20:38:01","modified_gmt":"2022-06-15T20:38:01","slug":"uremic-pruritus-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-trevi-therapeutics-kissei-pharma-neuroplast-sanwa-kagaku-kenkyusho-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/uremic-pruritus-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-trevi-therapeutics-kissei-pharma-neuroplast-sanwa-kagaku-kenkyusho-and-others_604181.html","title":{"rendered":"Uremic Pruritus Market is Projected to Boost at a Moderate Growth Rate by 2032 &#8211; DelveInsight | Key Companies &#8211; Trevi Therapeutics, Kissei Pharma, Neuroplast, Sanwa Kagaku Kenkyusho, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Uremic Pruritus Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies - Trevi Therapeutics, Kissei Pharma, Neuroplast, Sanwa Kagaku Kenkyusho, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Uremic Pruritus Market is Projected to Boost at a Moderate Growth Rate by 2032 - DelveInsight | Key Companies - Trevi Therapeutics, Kissei Pharma, Neuroplast, Sanwa Kagaku Kenkyusho, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Uremic Pruritus Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uremic Pruritus Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/div>\n<p style=\"text-align: justify;\">The <strong>Uremic Pruritus market<\/strong> report covers emerging drugs, current treatment practices, market share of the individual therapies, and current &amp; forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers &amp; barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Uremic Pruritus Market\" src=\"https:\/\/www.abnewswire.com\/uploads\/68c867480cd9b03d1b134fcb2acf6153.jpg\" alt=\"Uremic Pruritus Market\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus: An Overview<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Uremic pruritus (UP),<\/strong> also known as<strong> Chronic Kidney Disease-associated pruritus (CKD-aP)<\/strong>, is a debilitating symptom in patients with end-stage renal disease (ESRD). Of all the systemic disorders linked to pruritus, uremia is the most common. Itching in patients with advanced kidney failure or among patients on dialysis can be quite disabling, affecting sleep, interfering with work, and potentially compromising the quality of life.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><em>Currently, there are no universally accepted scales for measuring Uremic pruritus severity, characteristics, or its effect on the quality of life. In addition, there is no one particular itching profile that defines patients with Uremic pruritus.<\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p><em>According to estimates from the CDC, approximately <strong>15% of the adult population<\/strong> in the United States, or <strong>30 million people,<\/strong> suffer from CKD, with an estimated <strong>50% in stages III&ndash;V<\/strong>. Of the patients diagnosed with stage III&ndash;V CKD, approximately <strong>25%<\/strong> suffer from moderate-to-severe pruritus.<\/em><\/p>\n<\/li>\n<li><em>As per the study conducted by Olufemi Aina et al. (2017),<strong> Chronic Kidney Disease-Associated Pruritus (CKD-aP)<\/strong> is a distressing, often overlooked condition in patients with CKD and end-stage renal disease. It affects about <strong>40%<\/strong> of patients with end-stage renal disease and has been associated with poor quality of life, poor sleep, depression, and mortality.&nbsp;<\/em><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/uremic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Uremic Pruritus Market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><em><strong>Uremic Pruritus (UP) Market Size is anticipated to increase during the study period owing to the increasing prevalent population in the 7MM.&nbsp;<\/strong><strong>Extensive research and development activities of pharmaceutical companies developing the therapies will also significantly impact the market size.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\">The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted <strong>Uremic Pruritus market size<\/strong> by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers &amp; barriers, unmet needs, and emerging technologies.<\/p>\n<p style=\"text-align: justify;\">The report gives complete detail of the <strong>Uremic Pruritus market trend<\/strong> for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.<\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Uremic Pruritus market<\/strong> or expected to get launched during the study period. The analysis covers Uremic Pruritus market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the <strong>Uremic Pruritus Pipeline Development Activities<\/strong>. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus Therapeutics Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><em><strong>The Chronic Kidney Disease-Associated Pruritus (CKD-aP) market dynamics&nbsp;is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, and incremental healthcare spending across the world.<\/strong> <\/em><\/p>\n<p style=\"text-align: justify;\">The current pipeline of Chronic Kidney Disease-Associated Pruritus is limited as only a few companies are working on Chronic Kidney Disease-Associated Pruritus. This provides an opportunity for other companies to enter the market and grab a significant market share.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the Key Companies in the Uremic Pruritus (UP) Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Trevi Therapeutics<\/p>\n<\/li>\n<li>\n<p>Kissei Pharmaceutical<\/p>\n<\/li>\n<li>\n<p>Neuroplast<\/p>\n<\/li>\n<li>\n<p>Sanwa Kagaku Kenkyusho<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Uremic Pruritus (UP) Therapies covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>\n<p>Nalbuphine ER<\/p>\n<\/li>\n<li>\n<p>MR13A9<\/p>\n<\/li>\n<li>\n<p>Difelikefalin\/CR845<\/p>\n<\/li>\n<li>\n<p>SK-1405<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And many more.<\/p>\n<p style=\"text-align: justify;\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies&nbsp; &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Uremic Pruritus Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\">4. Uremic Pruritus Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Uremic Pruritus Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Uremic Pruritus Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Uremic Pruritus Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Uremic Pruritus Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Uremic Pruritus Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Uremic Pruritus Treatment<\/p>\n<p style=\"text-align: justify;\">11. Uremic Pruritus Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Uremic Pruritus Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Uremic Pruritus Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\">15. Uremic Pruritus Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\">16. Uremic Pruritus Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\">17. KOL Views on the Uremic Pruritus Market.<\/p>\n<p style=\"text-align: justify;\">18. Uremic Pruritus Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Uremic Pruritus Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\"><em><strong>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/uremic-pruritus-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Other Trending Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/preeclampsia-market\">Preeclampsia Market<br \/><\/a><\/strong>&ldquo;Preeclampsia Market&rdquo; research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Preeclampsia market trends in 7MM.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=uremic-pruritus-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-trevi-therapeutics-kissei-pharma-neuroplast-sanwa-kagaku-kenkyusho-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=uremic-pruritus-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-trevi-therapeutics-kissei-pharma-neuroplast-sanwa-kagaku-kenkyusho-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Uremic Pruritus Market Insights, Epidemiology, and Market Forecast 2032&#8221; report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Uremic Pruritus Market size, share, and trends in the seven &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/uremic-pruritus-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-trevi-therapeutics-kissei-pharma-neuroplast-sanwa-kagaku-kenkyusho-and-others_604181.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,417,406,404],"tags":[],"class_list":["post-604181","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604181","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=604181"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604181\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=604181"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=604181"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=604181"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}